ArticleExtracellular vesicle2025
Using common features of viruses and EVs for a novel EV-based lateral flow test for HIV.
Article in Extracellular vesicle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The similarities between extracellular vesicles (EVs) and viruses make them challenging to distinguish and separate into unique populations. A novel lateral flow test has been developed by utilizing these shared properties to improve at-home testing for HIV. By targeting EVs released from HIV infected cells (HIV-EVs) and HIV virus particles for immunocapture, which share common transmembrane proteins like tetraspanins, HIV proteins can be concentrated from blood samples in a lateral flow device. Others have described immunocapture of EVs by lateral flow; here we describe capture and lysis for downstream detection of specific HIV cargo for a sensitive antigen-only HIV test. We found that HIV antigens p24 and Nef are detected early in infection and may significantly improve the sensitivity of an at-home test format by utilizing EVs as a novel reservoir of HIV antigens.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.